Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cells transfected with leukemia-associated antigen RNA
- Development stage
- Unknown
- Lead developer
- Ludwig Maximilian University of Munich
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intravenous
01
Overview
Autologous dendritic cells transfected with leukemia-associated antigen RNA is an investigational cell-based immunotherapy developed by the Hospital of Ludwig Maximilians University Munich. The therapy involves generating autologous monocyte-derived dendritic cells (DCs) ex vivo from the patient's own CD14+ monocytes, which are then transfected via electroporation with in vitro-transcribed mRNA encoding leukemia-associated antigens (LAAs), specifically Wilms' Tumor protein 1 (WT1) and Preferentially Expressed Antigen in Melanoma (PRAME). These antigen-loaded mature DCs are re-administered to the patient to stimulate an AML-specific T-cell immune response. It was evaluated in a Phase 1 clinical trial (NCT01734304) for the treatment of acute myeloid leukemia (AML) in adult patients not eligible for allogeneic stem cell transplantation.
- Other names
- autologous dendritic cell vaccineWT1/PRAME-transfected dendritic cells
02
Targets
PRAME (Preferentially expressed antigen in melanoma)WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on autologous dendritic cells transfected with leukemia-associated antigen RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cells transfected with leukemia-associated antigen RNA.